Keros Therapeutics (KROS) Operating Margin (2019 - 2025)
Historic Operating Margin for Keros Therapeutics (KROS) over the last 6 years, with Q3 2025 value amounting to 107.87%.
- Keros Therapeutics' Operating Margin rose 150099200.0% to 107.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.67%, marking a year-over-year increase of 313592900.0%. This contributed to the annual value of 5938.96% for FY2024, which is 1066047500.0% up from last year.
- Keros Therapeutics' Operating Margin amounted to 107.87% in Q3 2025, which was up 150099200.0% from 219.16% recorded in Q2 2025.
- In the past 5 years, Keros Therapeutics' Operating Margin registered a high of 1576900.0% during Q1 2021, and its lowest value of 541000.0% during Q3 2023.
- Its 5-year average for Operating Margin is 59681.03%, with a median of 1750.62% in 2024.
- Its Operating Margin has fluctuated over the past 5 years, first tumbled by 2000000000bps in 2022, then surged by 2000000000bps in 2024.
- Quarter analysis of 5 years shows Keros Therapeutics' Operating Margin stood at 27.18% in 2021, then plummeted by -393bps to 134.03% in 2022, then tumbled by -24137bps to 32486.01% in 2023, then skyrocketed by 95bps to 1750.62% in 2024, then skyrocketed by 94bps to 107.87% in 2025.
- Its Operating Margin was 107.87% in Q3 2025, compared to 219.16% in Q2 2025 and 71.97% in Q1 2025.